clinical trial · NCT07701941
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast CancerPatritumab deruxtecanTrastuzumab deruxtecan
brief summary
The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.
started
Sep 17, 2026
primary completion
Jan 1, 2031
completion
May 1, 2032
last updated
Oct 1, 2026
official title
A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol